We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA Renews Canadian Distribution Agreement
Read MoreHide Full Article
York, PA-based DENTSPLY SIRONA Inc. (XRAY - Free Report) , a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
Stock Performance
The price performance of the stock has been unfavorable in the last three months. DENTSPLY SIRONA rose only 3.67%, underperforming the Zacks classified Medical/Dental-Supplies sub-industry’s gain of almost 9.16%. The current level compares unfavorably with the S&P 500’s return of 3.82% over the same time frame.
The estimate revision trend for the stock has been dismal, with 10 estimates moving south in the last two months and no estimate moving north. Notably, the current year estimate for the stock fell 2 cents to $2.83 per share over the same time frame. The company currently holds a Zacks Rank #3 (Hold).
Coming back to the news, the renewal agreement would be effective from Sep 1, 2017 through Dec 31, 2020. We feel the agreement is a smart move by DENTSPLY SIRONA as the preexisting distribution agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors. By including the aforementioned lines of products, the company would be able to take full advantage of Henry Schein’s distribution network in Canada. Henry Schein Canada's existing agreement with DENTSPLY SIRONA was originally initiated in Aug 2005.
Headquartered in York, PA, DENTSPLY SIRONA is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products.
Looking ahead, robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. However, higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration are also major risks in the near term.
Key Picks
A few other top-ranked stocks in the broader medical sector are Inogen Inc. (INGN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Luminex Corporation . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 99.5%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.4%. Notably, the stock represents an impressive one-year return of 99.5%.
Luminex has a long-term expected earnings growth rate of 16.25%. Additionally, the stock represents an impressive one-year return of 20.3%. Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
DENTSPLY SIRONA Renews Canadian Distribution Agreement
York, PA-based DENTSPLY SIRONA Inc. (XRAY - Free Report) , a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
Stock Performance
The price performance of the stock has been unfavorable in the last three months. DENTSPLY SIRONA rose only 3.67%, underperforming the Zacks classified Medical/Dental-Supplies sub-industry’s gain of almost 9.16%. The current level compares unfavorably with the S&P 500’s return of 3.82% over the same time frame.
The estimate revision trend for the stock has been dismal, with 10 estimates moving south in the last two months and no estimate moving north. Notably, the current year estimate for the stock fell 2 cents to $2.83 per share over the same time frame. The company currently holds a Zacks Rank #3 (Hold).
Coming back to the news, the renewal agreement would be effective from Sep 1, 2017 through Dec 31, 2020. We feel the agreement is a smart move by DENTSPLY SIRONA as the preexisting distribution agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors. By including the aforementioned lines of products, the company would be able to take full advantage of Henry Schein’s distribution network in Canada. Henry Schein Canada's existing agreement with DENTSPLY SIRONA was originally initiated in Aug 2005.
Headquartered in York, PA, DENTSPLY SIRONA is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products.
Looking ahead, robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. However, higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration are also major risks in the near term.
Key Picks
A few other top-ranked stocks in the broader medical sector are Inogen Inc. (INGN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Luminex Corporation . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 99.5%.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.4%. Notably, the stock represents an impressive one-year return of 99.5%.
Luminex has a long-term expected earnings growth rate of 16.25%. Additionally, the stock represents an impressive one-year return of 20.3%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>